Saturday, 31 October 2026European Markets

SELECTIRENTE And ARGAN Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - selectirente (seler.pa) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
selectirente (seler.pa) €88.00 4.73% 5.87%
argan (arg.pa) €77.10 4.07% 4.67%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. selectirente (seler.pa)

4.73% forward dividend yield and 5.87% return on equity

selectirente is a public real estate fund managed by sofidy. it invests in city center and suburb commercial properties, which should be located close to shopping malls. it primarily acquires properties in france. as of march 29, 2019, selectirente operates as a subsidiary of tikehau capital.

earnings per share

as for profitability, selectirente has a trailing twelve months eps of €2.32.

pe ratio

selectirente has a trailing twelve months price to earnings ratio of 37.93. meaning, the purchaser of the share is investing €37.93 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.87%.

more news about selectirente.

2. argan (arg.pa)

4.07% forward dividend yield and 4.67% return on equity

argan sa engages in designing, building, developing, owning, leasing, and managing logistical platforms in france. it is also involved in the development and management of land. the company's real estate property consists of a total area of 806,000 square meters. it serves shippers and logistics companies. the company was founded in 1993 and is based in neuilly sur seine, france.

earnings per share

as for profitability, argan has a trailing twelve months eps of €4.

pe ratio

argan has a trailing twelve months price to earnings ratio of 19.27. meaning, the purchaser of the share is investing €19.27 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.67%.

dividend yield

as stated by morningstar, inc., the next dividend payment is on mar 27, 2024, the estimated forward annual dividend rate is 3.15 and the estimated forward annual dividend yield is 4.07%.

moving average

argan's worth is higher than its 50-day moving average of €76.08 and below its 200-day moving average of €77.19.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, argan's stock is considered to be overbought (>=80).

more news about argan.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com